Fundraising FoxSV Life Sciences
Venture capitalBoston · 10 people tracked
Find your way into SV Life Sciences
Sign up to see every warm intro you have to SV Life Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SV Life Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fund manager profile
SV Life Sciences is a venture fund manager based in Boston. SEC filings show 3 venture funds on record, most recently SV Life Sciences Fund IV CF, L.P. ($421.4M offering) filed March 2022.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 10 people
from public directories
What they invest in
from 16 of 17 portfolio companiesBiotech ×10Healthtech ×9Medical Devices ×5AI & Machine Learning ×3Deep Tech ×2Digital Health ×1Hardware ×1Robotics ×1
HQs:United States×16
Investments · 17 tracked
founders shown can be your intro pathBy year:2025 · 12018 · 12017 · 32016 · 12014 · 32012 · 12011 · 212 dated
American Well operates a digital healthcare platform that connects patients, physicians, and healthcare professionals to provide remote clinical services, earning revenue through arrangements with healthcare organizations and clients who use its technology to deliver telehealth and related services.
HealthtechBoston, US
Ido Schoenberg(Executive Officer, Director)inRoy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)Phyllis Gotlib(President, International)inMark Hirschhorn(Executive Vice President, Chief Financial Officer and Chief Operating Officer)in
Co-investorsHanaco Venture CapitalMartin VenturesSV Health Investors
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsDementia Discovery FundForesite CapitalGV (Google Ventures)Dementia DiscoveryDolby Family VenturesLightstone Ventures+3 more
HealthtechSunnyvale, US
Thomas Afzal(Executive Officer, Director)
BoardPeter van der Velden(Director)inDan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
Board seatDavid Milne· per SEC Form D · $1.6M raise · filed Nov 2016
Co-investorsHLM Investment PartnersLumira VenturesSV Health Investors
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)
Board seatDavid B Milne· per SEC Form D · $950K raise · filed Sep 2017
Co-investorsAisling CapitalSaints CapitalSV Health InvestorsQuaker BioVentures
BiotechIrvine, US
Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)
BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)
Co-investorsEvidity Health CapitalFlying L PartnersRevelation PartnersHEALTHCARE ROYALTY PARTNERSVersant Venture AIV HoldingsVersant Ventures
Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.
AI & Machine LearningBiotechDeep TechVermont, US
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalMithril Capital ManagementPremji InvestSV Health Investors+1 more
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.
BiotechHardwareMedical DevicesLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsOrbiMedSV Health InvestorsBorealis VenturesMithril Capital ManagementNeomed ManagementPolaris Partners+1 more
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical DevicesSeattle, US
Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)
Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesLumira VenturesRC CapitalRex Health Ventures+2 more
CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.
BiotechHealthtechMedical DevicesMarlborough, US
Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)inAnjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephan S. Ogilvie(CEO)in
Co-investorsBioBritSaints CapitalSV Health InvestorsAccuitive Medical VenturesOxford Bioscience Partners
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsClarus Ventures
BiotechMt. Arlington, US
Paul Chaney(Executive Officer, Director)
BoardAbbie Celniker(Director)inDavid Guyer(Director)Bruce Peacock(Director)Kevin Starr(Director)inLutz Giebel(Director)
Co-investorsAstellas Venture Management LLCAgent CapitalSV Health InvestorsThird Rock Ventures
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalJeito CapitalLongwood Fund+4 more
BiotechCarlsbad, US
John Gordon Foulkes(Executive Officer, Director)
BoardMette Agger(Director)Peter Bisgaard(Director)Giovanni Ferrara(Director)Tiba Aynechi(Director)Michael Ross(Director)
Co-investorsNovartis Venture FundSV Health Investors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
1 IPOs · 3 acquisitions · showing 2American WellNYSE: AMWLAvitideacq. by Repligen
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SV Life Sciences Fund VI, L.P.LPs: New Mexico Educational Retirement Board | 2015 | — | 14.0% | 1.58x | 1.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| American Well | — | $27.50 | Jan 2021 | $25M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has SV Life Sciences made?
- SV Life Sciences has 17 tracked investments, 4 of which have exited, including 1 dated in the last 24 months.
- Where is SV Life Sciences located?
- SV Life Sciences is headquartered in Boston, US.